Business Description
Geron Corp
NAICS : 325412
SIC : 2836
ISIN : US3741631036
Share Class Description:
LTS:0IV3: Ordinary SharesTotal Employee Number:
258Description
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2.46 | |||||
Equity-to-Asset | 0.42 | |||||
Debt-to-Equity | 0.56 | |||||
Debt-to-EBITDA | -3.38 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -2.22 | |||||
Beneish M-Score | -1.73 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 416.8 | |||||
3-Year EBITDA Growth Rate | 40.5 | |||||
3-Year EPS without NRI Growth Rate | 34.5 | |||||
3-Year FCF Growth Rate | 20.8 | |||||
3-Year Book Growth Rate | 19.9 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 42.25 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 31.57 | |||||
9-Day RSI | 35.57 | |||||
14-Day RSI | 40.61 | |||||
3-1 Month Momentum % | 26.54 | |||||
6-1 Month Momentum % | -8.18 | |||||
12-1 Month Momentum % | 13.35 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 6.92 | |||||
Quick Ratio | 5.16 | |||||
Cash Ratio | 4.28 | |||||
Days Inventory | 2957.56 | |||||
Days Sales Outstanding | 72.26 | |||||
Days Payable | 286.48 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -17.9 | |||||
Shareholder Yield % | -1.03 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 93.51 | |||||
Operating Margin % | -17.25 | |||||
Net Margin % | -33.05 | |||||
EBITDA Margin % | -17.66 | |||||
FCF Margin % | -56.15 | |||||
OCF Margin % | -55.91 | |||||
ROE % | -28.6 | |||||
ROA % | -12.31 | |||||
ROIC % | -22.3 | |||||
3-Year ROIIC % | 79.25 | |||||
ROC (Joel Greenblatt) % | -47.26 | |||||
ROCE % | -7.99 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 9 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 20.29 | |||||
PS Ratio | 4.5 | |||||
PB Ratio | 4.05 | |||||
Price-to-Tangible-Book | 4.06 | |||||
EV-to-EBIT | -18.77 | |||||
EV-to-Forward-EBIT | 25.77 | |||||
EV-to-EBITDA | -19.41 | |||||
EV-to-Revenue | 3.43 | |||||
EV-to-Forward-Revenue | 2.17 | |||||
EV-to-FCF | -5.97 | |||||
Price-to-GF-Value | 0.2 | |||||
| Price-to-Net-Current-Asset-Value | 4.76 | |||||
Earnings Yield (Greenblatt) % | -5.33 | |||||
FCF Yield % | -13.05 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Geron Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 204.559 | ||
| EPS (TTM) ($) | -0.11 | ||
| Beta | 1.7706 | ||
| 3-Year Sharpe Ratio | -0.04 | ||
| 3-Year Sortino Ratio | -0.06 | ||
| Volatility % | 44.24 | ||
| 14-Day RSI | 40.61 | ||
| 14-Day ATR ($) | 0.074568 | ||
| 20-Day SMA ($) | 1.496385 | ||
| 12-1 Month Momentum % | 13.35 | ||
| 52-Week Range ($) | 1.0403 - 1.998 | ||
| Shares Outstanding (Mil) | 642.47 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Geron Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Geron Corp Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Annual report for 2026 | 2027-03-03 | In 168 days | ||
| Fourth quarter earnings conference call for 2026 | 2027-02-25 08:00 | In 163 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-25 | In 162 days | ||
| Third quarter earnings conference call for 2026 | 2026-11-05 08:00 | In 51 days | ||
| Third quarter earnings results for 2026 | 2026-11-05 | In 50 days | ||
| H.C. Wainwright 28th Annual Global Investment Conference | 2026-09-15 15:30 | 1.35 (-2.88%) | ||
| Guidance call for 2026 | 2026-09-09 08:00 | 1.52 (+1.33%) | ||
| Second quarter earnings conference call for 2026 | 2026-08-05 08:00 | 1.34 (-0.74%) | ||
| Second quarter earnings results for 2026 | 2026-08-05 | 1.34 (-0.74%) | ||
| Goldman Sachs 47(th) Annual Global Healthcare Conference | 2026-06-08 08:40 | 1.18 (+1.72%) |
Show
Entries
Geron Corp Frequently Asked Questions
What is Geron Corp(LTS:0IV3)'s stock price today?
The current price of LTS:0IV3 is $1.38. The 52 week high of LTS:0IV3 is $2.00 and 52 week low is $1.04.
When is next earnings date of Geron Corp(LTS:0IV3)?
The next earnings date of Geron Corp(LTS:0IV3) is 2026-11-05 Est..
Does Geron Corp(LTS:0IV3) pay dividends? If so, how much?
Geron Corp(LTS:0IV3) does not pay dividend.
Press Release
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers